Fukangren

Company Overview
Beijing Fukangren Biopharmaceutical Technology Co., Ltd. is an innovative company specializing in new drug research and development. Founded in 2000 and officially established in 2002, the company was originally located in Beijing Fengtai Science and Technology Park and moved to No. 30 Jinxing Road, Daxing District, Beijing in 2015. For many years, Fukangren has been dedicated to the research and development of innovative drugs and is at a leading level in the field of innovative drugs. Since 2002, the company has been continuously certified as a "Beijing High-tech Enterprise" and "National High-tech Enterprise", and has received honors such as "Biopharmaceutical Laboratory of Beijing International Enterprise Incubation Center", "Patent Engine Pilot Enterprise of Zhongguancun Science and Technology Park", and "Sustained-release Formulation Platform of Beijing Fengtai Science and Technology Park".
Research Equipment
Fukangren's total research area is nearly 3,000 square meters. Each laboratory is equipped with pilot-scale and scale-up equipment to meet the requirements of various stages of new drug development. The experimental center is equipped with a large number of research facilities. In addition, we have established extensive business partnerships with the Analytical Center of Peking University, Capital Medical University, and others, broadening our research resources.
Research Fields
Fukangren is committed to the development of new drugs both domestically and internationally. The business areas involved include the following:
1. High-difficulty generic drugs: imitation of drugs with certain technical challenges. 2. Patent-expired drug rush imitation and high-quality imitation. 3. Introduction of foreign drugs in research and on the market. 4. Innovative drugs: imitation and innovative drugs with independent intellectual property. 5. New formulations: sustained-release technology, poorly soluble drug formulations, and fat emulsions. 6. Undertaking industrialization of synthesis processes. 7. Technical improvement of major synthesis process projects. 8. Business consulting for new drug factories and workshops. 9. Consulting for topic selection and project initiation. 10. Consulting for patent affairs.
Domestic Cooperation
While focusing on independent innovation, Fukangren also cooperates extensively with domestic and foreign R&D institutions and manufacturers. Currently, Fukangren has integrated and expanded its research resources, establishing extensive and in-depth business relationships with many well-known domestic universities and more than 100 manufacturers. It has long-term cooperation with Tsinghua University, the School of Pharmaceutical Science and Technology of Tianjin University, Peking University, the Academy of Military Sciences, and other research institutions. Key cooperating institutions include Tsinghua University's Small Molecule Laboratory, Peptide Laboratory, and Polymer Laboratory; and Tianjin University's School of Pharmaceutical Science and Technology Small Molecule Laboratory and Biological Products Laboratory. In addition, it has cooperated with hundreds of well-known pharmaceutical companies in China.
International Cooperation
Globalization of new drug R&D is the tenet that Fukangren upholds. After years of external exchanges, Fukangren has extensively carried out cooperation and exchange in various fields, including: cooperation in foreign formulation technology, technical cooperation and import/export of APIs and intermediates, cooperation in medical device import business, cooperation in drug import and export, and joint development of innovative drugs. Currently, it has reached cooperation agreements with more than 20 foreign research institutions and enterprises.
Development Philosophy
Since its establishment, Fukangren has adhered to the belief of "Sincere Service, Scientific Innovation". It has accumulated a group of outstanding pioneers. The team cooperates sincerely and dares to innovate. All employees are working hard together to develop the company into an internationally innovative drug research institution and to fulfill their duties to the development of the national pharmaceutical industry and the improvement of the level of national drug use.